Welcome to our dedicated page for Lifevantage SEC filings (Ticker: LFVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LifeVantage Corporation (Nasdaq: LFVN) is a Delaware-incorporated health and wellness company that focuses on nutrigenomics and cellular activation, and its SEC filings provide detailed insight into its operations, governance, and financial performance. As a public company, LifeVantage files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and proxy statements on Schedule 14A, among other documents.
Through these filings, investors can review information about LifeVantage’s activator-based product portfolio, which includes the Protandim family, TrueScience Liquid Collagen, the MindBody GLP-1 System, P84, AXIO nootropic energy drink mixes, activation-supporting nutrients, the TrueScience skin and hair care line, and Petandim. The filings also describe the company’s direct selling model, under which independent Consultants sell products to Customers and share the business opportunity with entrepreneurs.
Current reports on Form 8-K document material events such as financial results announcements, executive officer changes, and other significant corporate developments. Definitive proxy statements (DEF 14A) provide detail on board composition, executive compensation, equity incentive plans like the 2017 Long-Term Incentive Plan, and matters submitted to stockholder votes, including director elections, say-on-pay proposals, and auditor ratification. Voting results for these proposals are also reported in 8-K filings.
On this page, LifeVantage filings are updated as they are made available through the EDGAR system. AI-powered tools summarize key sections of lengthy documents, helping readers understand topics such as revenue trends, non-GAAP measures like adjusted EBITDA and adjusted earnings per share, stock-based compensation plans, and governance structures without reading every line. Users can also review disclosures related to dividends, share repurchases, and risk factors referenced in the company’s periodic reports.
For those researching LFVN, this filings archive offers a structured view of LifeVantage’s regulatory history, financial reporting, and corporate decision-making, with AI-generated highlights to make complex filings more accessible.
LifeVantage Corporation filed a current report describing two key updates. The company issued a press release announcing financial results for the three and six months ended December 31, 2025, which is furnished as Exhibit 99.1. The report also discloses that President and Chief Executive Officer Steven R. Fife has decided to retire and will resign as CEO and from the board, with his resignation expected to be effective in April 2026. The company states that Mr. Fife’s decision to retire is not due to any disagreement regarding operations, financial policies, or practices, and additional details are provided in a second press release furnished as Exhibit 99.2.
LifeVantage Corporation reported weaker results for the quarter ended December 31, 2025 as revenue fell to
For the first six months, revenue was
Lifevantage Corp director Michael Beindorff reported gifting company stock to a family trust. On 11/25/2025, he transferred 7,819 shares of Lifevantage common stock in a transaction coded "G," which indicates a gift with a reported price of $0 per share.
After this transaction, he directly owned 27,570 shares and indirectly held 51,625 shares through the Michael A. Beindorff Trust, where he and his spouse are trustees. Additional indirect holdings include 126 shares held by his spouse as custodian for minor children and 5,500 shares held by his spouse.
LifeVantage Corporation disclosed that two senior executives plan to leave the company in December 2025. On December 3, 2025, Chief Marketing Officer Julie Boyster notified the company of her intention to resign from that role effective December 12, 2025 to pursue other business opportunities.
On the same date, Chief Information and Innovation Officer Todd Thompson informed LifeVantage that he intends to resign from his role effective December 24, 2025, also to pursue other business opportunities. These changes affect the leaders overseeing the company’s marketing and information/innovation functions.
LifeVantage Corp (LFVN)11/19/2025, a trust for which he and his spouse serve as trustees sold 12,607 shares of LifeVantage common stock at a weighted average price of $6.4198 per share, with individual trades executed between $6.39 and $6.48. After this transaction, he reported beneficial ownership of 43,806 shares held by the trust, 35,389 shares held directly, 126 shares held by his spouse as custodian for minor children, and 5,500 shares held by his spouse.
LifeVantage Corporation filed a Form S-8 to register securities for issuance under the LifeVantage Corporation 2017 Long‑Term Incentive Plan. The registration becomes effective upon filing in accordance with Rule 462(a).
The filing incorporates by reference the company’s most recent Form 10‑K, Form 10‑Q, and certain Form 8‑K reports. Exhibits include a legal opinion on the validity of the securities, auditor and counsel consents, and the plan document. The company states standard Delaware-law indemnification provisions for directors and officers and notes the SEC’s position that indemnification for Securities Act liabilities is unenforceable.
LifeVantage identifies itself as an accelerated filer and a smaller reporting company.
LifeVantage Corporation reported final results from its fiscal 2026 annual meeting held on November 6, 2025. Quorum was achieved with 9,571,454 shares (75.41%) represented out of 12,691,009 outstanding as of the record date.
All seven director nominees were elected. Stockholders approved, on an advisory basis, executive compensation with 7,420,820 votes for. They ratified Deloitte & Touche LLP as independent auditor with 9,539,267 votes for. An amendment to the 2017 Long‑Term Incentive Plan was approved with 5,382,441 votes for.
LifeVantage (LFVN) reported an insider equity grant. A director acquired 13,531 shares of common stock on 11/06/2025, reflected at $7.76 per share, which the filing notes equals the weighted average closing price over the ten trading days ending the day before the grant.
The grant will vest in a single installment on November 6, 2026, subject to the director’s continuous service. Following this grant, the director beneficially owns 23,999 shares, held directly.
LifeVantage (LFVN) reported a routine insider equity grant. Director Cynthia Latham acquired 13,531 shares of common stock on 11/06/2025 under the company’s outside director compensation program. The grant vests in a single installment on November 6, 2026, contingent on continuous service. The reported price of $7.76 reflects the weighted average closing price over the ten trading days preceding the grant date. Following this grant, her beneficial ownership stands at 64,879 shares, held directly.
Lifevantage (LFVN) reported a director equity grant. Director Raymond B. Greer acquired 13,531 shares of common stock on 11/06/2025 under the outside director compensation program at a price equal to the $7.76 weighted average closing price over the ten trading days ending the day before the grant.
The award will vest in a single installment on 11/06/2026, contingent on continued service. Following the grant, Greer beneficially owns 112,819 shares, held directly.
FAQ
What is the current stock price of Lifevantage (LFVN)?
What is the market cap of Lifevantage (LFVN)?
